The Next Governor Of Texas Will Find A Breast Cancer Cure: 
Dallas Texas (AP)--- The Texas Governor’s race is going to be one of the most important governor’s races in the United States. The next governor of Texas will be the governor responsible for making a breast cancer cure a reality.
Dallas Texas (AP)--- The Texas Governor’s race is going to be one of the most important governor’s races in the United States. The next governor of Texas will be the governor responsible for making a breast cancer cure a reality.Barron's Medical Journal Dedicates This Article To The Great Literary Master . . . " Gabriel Garcia Marquez " R.I.P
Wendy Russell Davis is an American lawyer and Democratic politician from Fort Worth, Texas. Davis represents District 10 in the Texas Senate. She previously served on the Fort Worth city council.
Gregory Wayne Abbott, known as Greg Abbott, is an American lawyer and politician. He is the 50th Attorney General of Texas and the Republican gubernatorial nominee in the general election scheduled on November 4, 2014
.
.
Barron’s Medical Journal is excited, the rest of the science and medical communities are coming on board with genomics science and genomic testing. For a example a genomics test called the cMethDNA assay, 
accurately detected the presence of cancer DNA in the blood of patients with metastatic breast cancers up to 95 percent of the time in laboratory studies. The findings were described in the April 15 issue of the journal Cancer Research.
accurately detected the presence of cancer DNA in the blood of patients with metastatic breast cancers up to 95 percent of the time in laboratory studies. The findings were described in the April 15 issue of the journal Cancer Research.
To design the test, Sukumar and her team scanned the genomes of primary breast cancer patients, as well as DNA from the blood of metastatic cancer patients. They selected 10 genes specifically altered in breast cancers, including newly identified genetic markers AKR1B1, COL6A2, GPX7, HIST1H3C, HOX B4, RASGRF2, as well as TM6SF1, RASSF1, ARHGEF7, and TMEFF2, which Sukumar's team had previously linked to primary breast cancer.
The test, developed by Sukumar, collaborator Mary Jo Fackler, Ph.D., and other scientists, detects so-called hypermethyation, a type of chemical tag in one or more of the breast cancer-specific genes present in tumor DNA and detectable in cancer patients' blood samples. Hypermethylation often silences Brought To You By 2014 Cadillac ELR
genes that keep runaway cell growth in check, and its appearance in the DNA of breast cancer-related genes shed into the blood indicates that cancer has returned or spread.
genes that keep runaway cell growth in check, and its appearance in the DNA of breast cancer-related genes shed into the blood indicates that cancer has returned or spread.
CPRIT Cancer Prevention Research Institute of Texas The next Texas governor has the CPRIT Cancer Prevention Research Institute of Texas. The Austin-based CPRIT was created in 2007 when Texas voters agreed to a US$3-billion initiative that would spend $300 million a year to advance basic research, reduce cancer rates and nurture Texas companies. Since then, the state agency has awarded 427 grants totaling more than $750 million, with $574 million designated for scientific research and the rest for commercialization and prevention. Its funding of innovative research has won accolades. Controversy erupted in May after Gilman, who won the 1994 medicine Nobel, tendered his resignation in a strongly worded letter criticizing a $20-million commercial ‘incubator’ grant that had been awarded without scientific review. Much of the grant was slated for a group led by Lynda Chin at the University of Texas MD Anderson Cancer Center in Houston, where Chin’s husband, Ronald DePinho, is president. CPRIT internal correspondence that was subsequently made public through freedom-of-information rules suggests that the grant criteria were tailored to improve Chin’s eligibility At the same time as the incubator grant was awarded, a set of grants recommended for approval by the CPRIT’s scientific council stalled. Gilman said that he would remain with the CPRIT until the autumn. Over the summer, the contentious $20-million grant was withdrawn for ‘re-review’, and provisions were made for scientific review of all commercial grants. The previously sidelined grants were approved (as were all grants recommended by reviewers), and a compliance officer was hired to prevent submission irregularities
Texas Based Sam Houston Biotech and other will have the resources and the intellectual property to develop a cure for cancer.
Sam Houston Breast Cancer Researchers and Scientist are ahead of the curve with several new technologies based on Nanoparticles and Semi Conductors Namely Genomics and treatments.
The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.
The result is that the ability to determine Targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data.
The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes —
plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3000.00.
plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3000.00.
The lower cost, along with increasing speed, has led to a huge increase in how much breast Cancer sequencing data is being produced.
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells
Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid Sam Houston Researchers Say that nanotechnology will allow them to run many diagnostic tests simultaneously.
Nanoparticles nanoshells is use to antibodies that recognize cancer cells. Sam Houston scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. The heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
Sam Houston minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences. Hybrid Sam Houston understands that Hyperthermia gold nanoshell Targeted breast cancer genomics at 40 for high risk women will reduce breast cancer at 60 years of Age. Training Genomics Counselor and Storing DNA Analysis in the cloud will allow Hybrid Sam Houston to say that Chemotherapy will help their breast cancer outcome or if Chemotheraphy and Hyperthermia will extend their life.
Baylor College Of Medicine and Dr. Rothberg really means is that he wants to do for DNA sequencing what Mr. Jobs did for computing — spread it to the masses. Dr. Rothberg is the founder of Ion Torrent, which last month began selling a sequencer it calls the Personal Genome Machine. While most sequencers cost hundreds of thousands of dollars and are at least the size of small refrigerators, this machine sells for just under $50,000 and is the size of a largish desktop printer The Ion Proton Sequencer, produced by San Francisco-based Life Technologies Corp., is currently one of just three worldwide—the others are being deployed at Baylor College of Medicine, in Houston, Texas, and the Broad Institute, in Cambridge, Mass. The machine, about the size of a laser printer, was developed in part by Yale alumnus Jonathan M. Rothberg, Ph.D.,
a pioneer in DNA sequencing technology. Most sequencers require weeks or months, and many thousands of dollars, to sequence a human genome. The Ion Proton’s power and speed are due to advanced semiconductor chips that capture the chemistry of a DNA sample in much the same way as a digital camera captures light. The new equipment promises to be a boon to many projects undertaken at Yale, including the new effort to uncover the causes of rare genetic diseases.
a pioneer in DNA sequencing technology. Most sequencers require weeks or months, and many thousands of dollars, to sequence a human genome. The Ion Proton’s power and speed are due to advanced semiconductor chips that capture the chemistry of a DNA sample in much the same way as a digital camera captures light. The new equipment promises to be a boon to many projects undertaken at Yale, including the new effort to uncover the causes of rare genetic diseases.
Companies like Illumina, will be a big part of the success of a breast cancer cure. Illumina goal is to apply innovative sequencing and array technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible.
With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service.
With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service.
As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative sequencing and array-based solutions for genomic analysis serve as tools for disease research, drug discovery, and the development of molecular tests in clinical labs.
Get ready Susan Komen and others a cure will happen during the next Texas Governors’ term.
No comments:
Post a Comment